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Background: Hemorrhagic events are frequent in patients on treatment with antivitamin-K oral anticoagulants due
to their narrow therapeutic margin. Studies performed with acenocoumarol have shown the relationship between
demographic, clinical and genotypic variants and the response to these drugs. Once the influence of these genetic
and clinical factors on the dose of acenocoumarol needed to maintain a stable international normalized ratio (INR)
has been demonstrated, new strategies need to be developed to predict the appropriate doses of this drug. Several
pharmacogenetic algorithms have been developed for warfarin, but only three have been developed for
acenocoumarol. After the development of a pharmacogenetic algorithm, the obvious next step is to demonstrate
its effectiveness and utility by means of a randomized controlled trial. The aim of this study is to evaluate the
effectiveness and efficiency of an acenocoumarol dosing algorithm developed by our group which includes
demographic, clinical and pharmacogenetic variables (VKORC1, CYP2C9, CYP4F2 and ApoE) in patients with venous
thromboembolism (VTE).
Methods and design: This is a multicenter, single blind, randomized controlled clinical trial. The protocol has been
approved by La Paz University Hospital Research Ethics Committee and by the Spanish Drug Agency. Two hundred
and forty patients with VTE in which oral anticoagulant therapy is indicated will be included. Randomization (case/
control 1:1) will be stratified by center. Acenocoumarol dose in the control group will be scheduled and adjusted
following common clinical practice; in the experimental arm dosing will be following an individualized algorithm
developed and validated by our group. Patients will be followed for three months. The main endpoints are: 1)
Percentage of patients with INR within the therapeutic range on day seven after initiation of oral anticoagulant
therapy; 2) Time from the start of oral anticoagulant treatment to achievement of a stable INR within the
therapeutic range; 3) Number of INR determinations within the therapeutic range in the first six weeks of treatment.
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Discussion: To date, there are no clinical trials comparing pharmacogenetic acenocoumarol dosing algorithm
versus routine clinical practice in VTE. Implementation of this pharmacogenetic algorithm in the clinical practice
routine could reduce side effects and improve patient safety.
Trial registration: Eudra CT. Identifier: 2009-016643-18.
Keywords: Pharmacogenetic, Acenocoumarol, HematologyBackground
Antivitamin-K oral anticoagulants, which include aceno-
coumarol, are highly effective drugs for the treatment of
venous thromboembolism (deep venous thrombosis or
DVT, and pulmonary thromboembolism or PTE), atrial
fibrillation and patients with mechanical heart valves [1].
However, hemorrhagic events are frequent [2,3] due to
the narrow therapeutic margin of these drugs and the
considerable interindividual variability in the pharmaco-
kinetics and pharmacodynamics of these drugs.
Studies performed with warfarin and acenocoumarol
have shown that the relationship between the genotypic
variants CYP2C9 and VKORC1 account for approxi-
mately 30% to 40% of the variability in the response to
these drugs [4-6] while various clinical factors explain
between 15% and 20% of the variability. More recently,
other polymorphisms have been identified that influence
the doses of warfarin and acenocoumarol necessary to
maintain a stable international normalized ratio (INR).
The CYP4F2 will hydroxylate the side chain as the first
step in the inactivation of vitamin E, although its role in
the vitamin K/acenocoumarol pathway is not yet known
[7-10]. Apolipoprotein E (ApoE), in turn, mediates the
uptake of lipoproteins rich in vitamin K by the liver and
other tissues [11,12].
Once the influence of these genetic and clinical factors
on the dose of acenocoumarol needed to maintain a
stable INR has been demonstrated, new strategies need
to be developed to predict the appropriate doses of this
drug. Several pharmacogenetic algorithms have been
developed for warfarin [13-22] and three have been
developed for acenocoumarol. The first algorithm for
acenocoumarol [23] is based on a score generated with
genetic variants of CYP2C9 and VKORC1. The second
algorithm was published by the EU-PACT group [24]
and includes clinical (age, gender, weight, height and use
of amiodarone) and genetic variables (CYP2C9 and
VKORC1). Our research group has developed a third al-
gorithm for individualization of the acenocoumarol dose
in patients with VTE using a multiple linear regression
analysis in a derivation cohort (n = 117) that includes
clinico-demographic variables (age, body mass index,
use of amiodarone and enzyme inducers) and poly-
morphisms of the VKORC1, CYP2C9, CYP4F2 and ApoE
genes [25]. The clinical factors explained 22% of thedose variability, which increased to 60.6% when pharma-
cogenetic information was included (P <0.001). In the
testing cohort (n = 30), clinical factors explained a 7% of
the dose variability, compared to 39% explained by the
pharmacogenetic algorithm. The pharmacogenetic algo-
rithm correctly predicted the stable dose in 59.8% of the
cases (derivation cohort) versus only 37.6% predicted by
the clinical algorithm (95% CI: 10 to 35). We have
implemented this algorithm in a public web page (www.
acenocoumaroldosing.com).
After the development of a pharmacogenetic algo-
rithm, the obvious next step is to demonstrate its effec-
tiveness and utility by means of a randomized controlled
trial. One such trial in the USA is being performed
with warfarin: NCT01178034 (ClinicalTrials.gov), and
includes patients with atrial fibrillation. Another trial has
been completed: NCT00511173, which included patients
with atrial fibrillation, pulmonary embolism and deep vein
thrombosis. In Europe, there is an ongoing clinical trial to
test whether the dosing algorithms for coumarin anticoagu-
lants (including acenocoumarol) improves the clinical out-
comes for patients [26].
Our group proposes this randomized clinical trial that
compares the standard dosing of acenocoumarol with
the adjustment based on the developed acenocoumarol
dosage algorithm (Eudra CT: 2009-016643-18).
Methods
Design and setting
The clinical trial was designed as a pragmatic, randomized,
parallel two-arm, single blind trial to compare the indivi-
dualized adjustment of acenocoumarol dosage using a phar-
macogenetic algorithm versus the standard adjustment, in
patients initiating oral anticoagulation for the treatment of
venous thromboembolism. The follow-up period will be
three months (Figure 1). The study will be performed in five
separate hospital centers in the Community of Madrid
(Spain). The recruitment period started in March 2011 and
is scheduled to end in the fourth quarter of 2012.
Study population
The target population is patients with new diagnoses of
pulmonary thromboembolism and/or deep vein thrombosis
diagnosed using objective imaging tests (CT angiography,
venous Doppler ultrasound), who require anticoagulant
Figure 1 Flowchart of study procedures.
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inclusion criteria and none of the exclusion criteria.
Inclusion criteria
 Male and female patients who are diagnosed with
VTE (PTE and/or DVT) who will start
anticoagulant therapy with acenocoumarol.
 Target INR between 2 and 3.
 Over 18 years of age.
 Women of childbearing age should take effective
contraceptive measures (barrier methods) to avoid
pregnancy during the treatment with acenocoumarol.
 Subjects may give their written consent to
participate in the study once they have received
information on the design, goals and possible risks
of the study and are made aware that they can
withdraw from the study at any time.
Exclusion criteria
 Patients anticoagulated with acenocoumarol at the
time of inclusion (≥2 doses).
 Pregnant or breastfeeding women.
 Patients with renal failure (creatinine clearance
≤30 ml/min).
 Patients with advanced liver failure (stage C of
Child-Pugh).
 Patients with a life expectancy of less than six months.Definition of the intervention
Once included in the clinical trial, patients will be ran-
domly assigned to the experimental or control groups.
Initially, all patients will receive treatment with low mo-
lecular weight heparins (LMWH) along with the stand-
ard acenocoumarol dose established according to age,
for a maximum of three days (the time required to ob-
tain the genotyping result). Subsequently, dose adjust-
ment will be different in the two groups:
Patients assigned to the experimental strategy will re-
ceive the regimen determined by the pharmacogenetic
algorithm, which includes demographic (age, gender,
weight and height), clinical (concomitant medication)
and pharmacogenetic (polymorphisms of CYP2C9,
VKORC1, APOE and CYP4F2) variables [25]. INR is also
taken into account.
Patients assigned to the control strategy will receive
doses according to the standard procedure in routine
clinical practice.
As a guide for handling and adjusting the acenocou-
marol dosages, the researchers will be referred to the
local guidelines developed in ‘Area 5’ for the manage-
ment of patients treated with acenocoumarol.
Objectives
Primary
To evaluate the effectiveness of an acenocoumarol dos-
ing algorithm that incorporates demographic, clinical
and pharmacogenetic variables of patients with venous
thromboembolism.
Secondary
 To evaluate the safety of the incorporation of
genetic data in the dose adjustment, by comparing
the frequency of appearance of relevant clinical
events in patients whose dosage is adjusted by
means of the designed algorithm versus standard
clinical practice.
 To evaluate the efficiency of implementing an
acenocoumarol dosing algorithm that incorporates
pharmacogenetic variables. To accomplish this, we
intend to perform an economic analysis of the
incorporation of the genotypic determinations




 Percentage of patients with an INR within the
therapeutic range (INR between 2 and 3) on day
seven after the initiation of treatment with
acenocoumarol.
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therapy to get a stable INR within the therapeutic
range (INR within the therapeutic range for three
consecutive measurements for at least two weeks,
with a maximum difference between the daily
average doses of 10%).
 Number of INRs within the range in the first six
weeks of treatment.
 Number of INRs within the range during the three
months of the study.
Secondary
 Proportion of time within the therapeutic range,
using a linear interpolation method [27].
 Number of special INR measurements (those that
are performed in addition to the scheduled
measurements in the program of visits established in
this protocol: days 0, 3, 7, 15, 30, 60 and 90).
Safety
 Proportion of patients with relevant adverse events
during the first three months following the start of
oral anticoagulation. These events include the
following: INR >4 or <1.5; need for vitamin K;
bleeding episode; thromboembolic event; need for
LMWH; acute myocardial infarction; acute stroke;
and death from any cause.
Pharmacoeconomic evaluation
 The pharmacoeconomic evaluation will be
performed according to a parallel and independent
protocol with special consideration of the direct
costs associated with the health care of these
patients.
Study procedures
The various study visits will be distributed as shown in
Table 1:
Preselection phase: The patients with VTE will be
identified in the emergency department or hospital ward
within the first 48 hours of the VTE diagnosis (PTE and/
or DVT) and will be checked to ensure they meet the se-
lection criteria.
Before any specific study procedure is performed, the
patient will receive the information verbally and in writ-
ing through the patient information sheet. The patient
must consent to participation in the study in writing
(two copies). The patient will keep a copy of the infor-
mation sheet and the informed consent once they have
been signed. Once patients have been included in the
study, the medical monitor will be informed of their in-
clusion and the randomization envelope will be opened
to determine the study group to which they will belong.Patients who were considered for inclusion but were not
admitted to the study will be registered in a patient-log
along with the cause for their non-inclusion (lack of
informed consent, selection criteria, practical issues, and so
on).
Inclusion phase (days −3 or −2): After recording in the
case report file (CRF) that the patient meets the selec-
tion criteria, the patient's clinical situation will be
reviewed and the following information about the med-
ical history will be recorded in the CRF: personal history
and anamnesis, including concomitant medication with
current dosage and regimen, and complete physical
examination which will include height and weight. The
patient will also be provided with a card listing basic in-
formation about the trial, what to do in the event of se-
vere adverse events and the research team's telephone
numbers. The start of the treatment with acenocoumarol
will occur on day −3 or −2, according to standard clin-
ical practice. The following dosages will be provided to
the researcher as a guideline for the local recommenda-
tions: 2 mg a day for patients below 65 years of age and
1 mg a day for older patients or those with risk factors.
Pharmacogenetic specimen collection: During recruit-
ment, a blood sample will be taken from the patient
(two tubes of 5 mL EDTA K3) and will be sent by mes-
senger to the laboratory where the patient's genotype
will be determined.
The samples do not require special conservation or
transportation conditions. In the event that the messen-
ger collects the sample the day after extraction, it is
recommended that the blood sample be stored in a
refrigerator.
The results will be sent by email within 48 hours. The
medical monitor will ensure compliance with these




– Control group: The INR will be determined in a
capillary blood sample by means of a CoaguCheckW
portable coagulometer (Roche FarmaSA, Madrid,
SPAIN), and the acenocoumarol dosage will be
determined according to standard clinical practice.
– Intervention group: At this time, the results of the
genotyping will have returned and the
acenocoumarol dose will be calculated according to
the developed algorithm.
Days 3 and 7 ± 1: The INR will be determined (capil-
lary blood sample analyzed with a portable coagul-
ometer) in both groups, and the acenocoumarol dosage
will be adjusted if necessary. Control group patients will
follow the dosage indications according to the standard
Table 1 Study timeline





Physical examination √ √
Blood samples for pharmacogenetics √
Randomization √
Acenocoumarol dosing (initiation/adjustment)a √ √ √ √ √ √ √
INR determination √ √ √ √ √ √ √
Evaluation of side effects √ √ √ √ √ √ √
aIn order to perform appropriate dose adjustments, additional visits can be scheduled as needed, at the discretion of the clinical researcher.
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day 7 ± 1 and day 15 ± 3, depending on the length of the
hospital stay. Patients included in the intervention group
will have their acenocoumarol regimen readjusted
according to the developed algorithm and will be sched-
uled for visits on day 3, 7 ± 1 and 15 ± 3, depending on
the length of the hospital stay.
INR measurements will be performed on both groups
and additional visits deemed appropriate for good con-
trol of the anticoagulation will be arranged. Any changes
made to the dosage and all INR measurements will be
recorded in the CRF and the medical records.
Visit days 15 ± 3, 30 ± 5, 60 ± 7 and 90 ± 7: During each
visit, and after determining the INR (capillary blood
sample analyzed with a portable coagulometer), the dos-
age will be adjusted. The patient's next scheduled visit
will be arranged, and an additional visit will be sched-
uled if necessary. Adverse events will be recorded during
all visits, as contained in “Adverse events” section of this
protocol. During the final visit, a complete physical
examination will also be performed.
Concomitant medication
– After the diagnosis, as recommended by
international guidelines on the treatment of VTE, all
patients (both the control and experimental groups)
will receive low molecular weight heparins (LMWH)
for at least seven days.
– All other medication that the patient is taking will
be recorded in their medical history and CRF, as
well as any changes they present during the course
of the study. We will record the brand name of the
medication, the active ingredient, dosage schedule,
start or change in treatment, end of treatment and
whether there has been any resolution of the
problem that caused the start or change of
treatment.As is standard practice, the study's medical researchers
will take into account this change in medication when
adjusting the acenocoumarol dosage for both the experi-
mental and control group.Randomization
The randomization was performed using a masked
randomization scheme, in a 1:1 ratio, in blocks of four
patients and stratified by center. Based on this scheme,
randomization envelopes were created for each center.
The patient's code was written on the outside of these
envelopes (center and patient codes) and inside the
opaque sealed envelope was a card indicating the study
group to which the patient was assigned. The envelopes
and card were stored in the investigator file.Masking
The study is single blind, and under no circumstance
does the patient know the group to which they have
been assigned. The medical researchers are unaware of
the randomization scheme. Although there is a risk of
unmasking the patient, and the lack of masking for the
physician may affect the evaluation variables, we believe
that total masking is not feasible in a study using a prag-
matic approach.Genotyping
In the recruitment visit, two 3 ml tubes of blood will be
collected from all participants for genotyping of
CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910),VKORC1
(−1639 G→A = rs9923231), CYP4F2 (rs2108622), and
APOE (8016 C→ T = rs7412), using a previously devel-
oped multiplex technique [28]. Measurements will be
performed in a centralized manner at the Laboratory of
Population Genetics of the Department of Forensics at
the Universidad Complutense de Madrid.
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Anticoagulation monitoring
The INR (International Normalized Ratio) will be deter-
mined using a portable coagulometer (CoaguCheckW,
Roche FarmaSA, Madrid, SPAIN)) during the visits on
days 0, 3, 7, 15, 30, 60 and 90, to verify that the patients
are properly anticoagulated and to make the necessary
dose adjustments. Dosing adjustments will be performed
according to standard clinical practice. For the experi-
mental group, the genetic results will also be taken into
account.
If clinically necessary, additional INR measurements
and visits will be performed according to standard clin-
ical practice.
Laboratory safety determinations
A laboratory analysis including hemogram, biochemistry
and coagulation will be performed on the second visit (day
0) and on the eighth or final visit (day 90 ± 7). A hard copy
of the results must be signed and dated by the applicant
researcher. Results with values outside the normal range
will be evaluated by the researching physician who will in-
dicate whether they are clinically relevant or not. Only
clinically relevant results will be recorded in the CRF.
Any additional analysis during any of the study visits,
requested either by the researcher or other physician,
will be recorded in the medical history and CRF along
with the reason for the request. A copy of the analysis
will be attached to the patient's medical record.
Adverse events
Any adverse event (not necessarily related to the use of
acenocoumarol) will be recorded in the case report form
and will be defined as a serious adverse event if it places
the patient's life in danger and/or requires or prolongs
hospitalization (for example, a major hemorrhagic event).
Hemorrhages will be categorized as major or minor,
according to the classification for hemorrhagic events of
the International Society on Thrombosis and Haemosta-
sis (ISTH) [29]. We will use the Naranjo et al. algorithm
[30] to determine any causal relationship between the
adverse event and the study treatment.
Withdrawal criteria
The patient can discontinue their participation in the
study at any time. The research doctor, in his or her
opinion or judgment, may also withdraw a patient from
the study if required by the patient's clinical situation or
if the patient does not comply with the protocol. The
onset of chronic disease during the study will result in
exclusion of the subject. The continuation of the patient
in the study after the onset of acute disease will be at
the discretion of the researcher, taking into account thepatient's safety and the influence of the disease and/or
its treatment on the evaluation variables.
Sample size calculation
We need 97 subjects per group to complete the study in
order to detect an absolute difference of 20% in the num-
ber of patients who are within the therapeutic range on
the seventh day after starting the treatment. For this calcu-
lation, we have set an alpha error of 0.05 and a beta error
of 0.2, and we assume that 40% of the patients will be
within the desired INR, and expect this to increase to 60%
in the experimental group. Given the risk of drop-out, the
number of patients per group will increase by 20%, placing
the recruitment objective at 120 patients per group.
According to Caraco et al. [31], pharmacodynamic
stabilization with warfarin in the standard control group
was achieved in 40.2 ± 21 days. For a reduction in ten
days in the experimental group and alpha and beta
errors of 0.05 and 0.2 respectively, the required number
of patients per group will be 70.
Statistical analysis
All recruited patients will be included in the main ana-
lysis, following an ‘intention to treat’ (ITT) strategy. For
the ITT analysis, patients lost to follow up will be classi-
fied in the following way: 1) patients lost before the sev-
enth day will be considered to be outside the therapeutic
range; 2) patients lost before the last visit and that have
not reached the stable INR will be considered not to be
in stable dosing; 3) all lost visits, the INR will be
accounted as being out of the therapeutic range. In
addition, we will perform a per protocol analysis on all
patients who can be monitored for the three month
period planned for the study and who have not missed
more than one intermediate follow-up visit.
To compare the analysis variables between both
groups, a contrast test of the hypothesis will be appro-
priate based on the normality of the sample (Kolmo-
gorov-Smirnov test), with a Cox regression for
dichotomous variables or Kaplan-Meier curves for repre-
senting results whenever possible. A regression model
(linear or logistic, as appropriate) will be performed
when necessary to correct for possible confounding fac-
tors. To determine the difference between the two
groups in the proportion of time within the therapeutic
range, we will use the linear interpolation method pro-
posed by Rosendaal et al. [27]. Finally, we will perform a
regression model stratified by center. The value P <0.05
will be established as statistically significant, adjusting
for multiple comparisons whenever necessary.
The cost-effectiveness analysis will be performed
according to a parallel and independent protocol, with
special consideration of the direct costs associated with
the health care of these patients.
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The researchers will adhere strictly to the provisions of
this protocol and will complete the case report forms.
The study will be performed according to the recom-
mendations for clinical studies and the evaluation of
drugs in humans, as contained in the Declaration of Hel-
sinki (revised in successive world assemblies) and in the
current Spanish and European legislation on clinical
studies and patient data confidentiality. The study will
follow the principles of Good Clinical Practice. This
study has been approved by the Clinical Research Ethics
Committee of the Hospital Universitario La Paz (Madrid,
Spain) and by the Spanish Agency of Medication and
Health Products and has been registered in Eudra CT
(Eudra CT: 2009-016643-18).Discussion
Anticoagulant therapy with acenocoumarol is associated
with a high incidence of hemorrhagic complications as
well as therapeutic failure (new thrombosis) [1]. These
complications are the result of the high interindividual
variability in the doses of acenocoumarol required to
achieve stable anticoagulation and the time required to
reach the steady state of the drug, which according to
Caraco et al. [31], may require 40.27 days (95% CI, 35.9
to 44.6 days) for warfarin.
One of the strategies for reducing this time and
thereby increasing both the efficacy and safety of these
drugs is the use of dosing algorithms that include demo-
graphic, clinical and genetic variables. These algorithms,
several of which have been published for warfarin [13-22]
and only three of which have been published for ace-
nocoumarol [23-25], must be validated through rando-
mized clinical trials in order to demonstrate their efficacy
and evaluate their effectiveness, as well as the feasibility
of their implementation in standard clinical practice.
There are two on-going clinical trials, one in the USA
using warfarin, and another in Europe (EU-PACT) eva-
luating algorithms for acenocoumarol, phenprocoumon
and warfarin [26].
Our clinical trial has several relevant differences from
the studies underway in the USA (in addition to the
anticoagulant used) and in Europe. Firstly, our algorithm
is the only one to consider the CYP4F2 and ApoE genes,
in addition to the more common demographic, clinical
(age, BMI and concomitant treatment with amiodarone
and metabolic inducers) and genetic (CYP2C9 and
VKORC1) variables. Secondly, the study population only
includes patients with VTE. These patients, analyzed as
a whole, tend to be younger (although they have a wider
age range) and have fewer concurrent conditions [32].
Clearly, this implies the theoretical advantages of greater
homogeneity of the included sample and a smallersample size required. In contrast, the extrapolation of
results to patients with atrial fibrillation or valve replace-
ments may be compromised.
Another aspect to consider is that the usefulness of
the genetic determination may be more important for
patients with VTE, given that it is important to achieve a
therapeutic range in the shortest time possible because
the risk of progression, recurrence and death due to PTE
is greater in the first weeks after the diagnosis [33-35].
Furthermore, the risk of bleeding is also greater at the be-
ginning of treatment; 62.5% of hemorrhages occur during
the first 15 days of treatment and 79.2% occur during the
first month (median, 11 days). In addition, approximately
50% of patients in therapy with anti-vitamin K have an
INR >3 [36].
In addition, the improved variables that reflect appro-
priate anticoagulant control (time within the appropriate
INR, the number of INRs in the range, and so on) could
decrease the visits required for necessary monitoring
and therefore improve the patient's quality of life and
the cost of the entire process. Finally, the time required
with VTE to properly adjust the oral anticoagulant dose
(with a frequency greater than one month) is a substan-
tial part of the total recommended treatment (three to
six months). However, these two aspects are less relevant
in the case of atrial fibrillation and valve replacement, in
which the short-term risk of ineffectiveness is much
lower and anticoagulation is required for life.
We selected appropriate anticoagulant control as the
primary objective, including variables such as the per-
centage of patients within the therapeutic range in the
short, medium and long-term or the time required to
achieve control. This represents a limitation compared
with the use of hard clinical variables (hemorrhages, re-
currence of VTE, the progression of PTE and/or the
presence of post-phlebitic syndrome). The decision to
establish this primary objective was based on logistical
reasons and due to its validity as a subrogated endpoint.
One of the logistical reasons was the need to perform
the genotypic determinations in a centralized laboratory
and within a short period of time (at most two days).
Therefore, the recruitment centers had to be concen-
trated in the city of Madrid or its suburbs. This in turn
places limitations on the number of patients who could
be recruited given that the study population is limited to
that of the centers. Similarly, for financial reasons, the
recruitment of several thousand patients was out of our
reach. There is compelling evidence that maintaining
an INR within the therapeutic range is a valid objec-
tive of anticoagulant therapy and is linked with clinical
end-points of interest, and as such it is used routinely
as a control treatment [37-40]. When implementing
pharmacogenetic techniques and dosing algorithms, it is
important to consider that local issues related to the
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ferences and differences in the healthcare system are of
great importance.
In summary, the proposed clinical trial will constitute
an important proof of the usefulness of dosing algo-
rithms that include pharmacogenetic variables.Trial status
This protocol was authorized on 18 March 2010 by the
Spanish Medicine Agency in its initial version, with sub-
sequent changes. The protocol described here corre-
sponds to version 5. The Ministry of Health granted
partial support for the implementation of the trial (pro-
ject TRA-010), and CAIBER (Spanish Platform for Clin-
ical Trials) was responsible for the monitoring and
coordination of the trial and also partially financed the
implementation of the trial. The first patient was
recruited in 21 March 2011 and currently, a total of 85
patients have been included. We plan to continue re-
cruitment until December 2012.APPENDIX: Trial Investigation Group
• Trial Coordination: Carcas Sansuán, Antonio J.
• Clinical Researchers:
○ Hospital Universitario La Paz:
▪ Department of Clinical Pharmacology: Alberto M.
Borobia, Jesús Frías Iniesta, Elena Ramírez García, Marta
Velasco, Hoi Y. Tong.
▪ Emergency Department: Manuel Quintana Díaz,
Ana Martínez Virto, Sara Fabra Cadenas, Manuel Gon-
zález Viñolis.
▪ Department of Internal Medicine: Carmen Fernán-
dez-Capitán, Alicia Lorenzo, Maria Ángeles Rodríguez
Dávila.
○ Hospital Universitario La Princesa:
▪ Department of Clinical Pharmacology: Francisco
Abad-Santos, Dolores Ochoa, Igone Marrodan, Isabel
Moreno, Manuel Román, Carmen Verge.
▪ Department of Internal Medicine: Carmen Suarez
Fernández, Nuria Ruiz-Giménez.
○ Hospital Infanta Sof ía:
▪ Department of Internal Medicine: Jorge Gómez Cer-
ezo, Olga Madridano, Mar Martín del Pozo.
○ Fundación Jiménez Díaz:
▪ Department of Hematology: Pilar Llamas Sillero.
○ Hospital 12 de Octubre:
▪ Department of Internal Medicine: Agustín Blanco
Echevarría.
• Pharmacogenetic determinations:
○ Universidad Complutense de Madrid: Eduardo
Arroyo Pardo, Ana Maria López Parra, Carlos Baeza.
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